Travelers' diarrhea: An update on susceptibility, prevention, and treatment

Current Gastroenterology Reports

Volumn 10, Issue 5, 2008, Pages 473-479

  Cabada, Miguel M ^a   White, A Clinton ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA DEFENSIN; ALPHA DEFENSIN 1; ALPHA DEFENSIN 3; ALPHA DEFENSIN 4; ALPHA DEFENSIN 5; ALPHA DEFENSIN 6; ANTIBIOTIC AGENT; AZITHROMYCIN; BACTERIAL VACCINE; BETA DEFENSIN 4; CHOLERA VACCINE; CYTOKINE; INTERLEUKIN 8; LACTOFERRIN; LEVOFLOXACIN; LOPERAMIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN FUT2; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAXIMIN; SECRETORY PROTEIN; UNCLASSIFIED DRUG; VIRUS RECEPTOR;

ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; CAMPYLOBACTER JEJUNI; CLINICAL TRIAL; DRUG RECEPTOR BINDING; ENTEROPATHOGENIC ESCHERICHIA COLI; GENE MUTATION; GENETIC CODE; GENETIC PREDISPOSITION; GENETIC RISK; HUMAN; IMMUNOREGULATION; INFECTION RISK; INNATE IMMUNITY; MONOTHERAPY; NONHUMAN; NOROVIRUS; REVIEW; SALMONELLA; SHIGELLA; SINGLE NUCLEOTIDE POLYMORPHISM; TRAVELLER DIARRHEA; VIRUS IMMUNITY; ARTICLE; DIARRHEA; DISEASE PREDISPOSITION; PHYSIOLOGY; TRAVEL;

DIARRHEA; DISEASE SUSCEPTIBILITY; HUMANS; INTERLEUKIN-8; TRAVEL;

EID: 58149357410     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-008-0087-7     Document Type: Review

References (49)

1. United Nations WorFd Tourism Organization: World tourist arrivals: from 800 million to 900 million in two years. UNWTO World Tourism Barometer 2008, 5:1, 3-4. Available at http://www.unwto.org/facts/eng/ barometer.htm. Accessed March 30, 2008.
2. World Trade Organization: International Trade Statistics 2007. Geneva, Switzerland: World Trade Organization; 2007. Available at http://www.wto.org/english/res_e/statis_e/statis_e.htm. Accessed April 9, 2008.
3. Steffen R, van der Linde F, Gyr K, Schar M: Epidemiology of diarrhea in travelers. JAMA 1983, 249: 1176-1180.
4. Jiang ZD, Lowe B, Verenkar MP, et al.: Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay). J Infect Dis 2002, 185: 497-502.
5. Tribble Dr, Sanders JW, Pang LW, et al.: Traveler's diarrhea in Thailand: Randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin Infect Dis 2007, 44: 338-346.
6. Chapin AR, Carpenter CM, Dudley WC, et al.: Prevalence of norovirus among visitors from the United States to Mexico and Guatemala who experienced travelers' diarrhea. J Clin Microbiol 2005, 43: 1112-1117.
7. Taylor DN, Bourgeois AL, Ericsson CD, et al.: A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. Am J Trop Med Hyg 2006, 74: 1060-1066.
8. ten Hove R, Schuurman T, Kooistra M, et al.: Detection of diarrhoea-causing protozoa in general practice patients in The Netherlands by multiplex real-time PCR. Clin Microbiol Infect 2007, 13: 1001-1007.
9. Sjöling A, Wiklund G, Savarino SJ, et al.: Comparative analyses of phenotypic and genotypic methods for detection of enterotoxigenic Escherichia coli toxins and colonization factors. J Clin Microbiol 2007, 45: 3295-3301.
10. Yang JR, Wu FT, Tsai JL, et al.: Comparison between O serotyping method and multiplex real-time PCR to identify diarrheagenic Escherichia coli in Taiwan. J Clin Microbiol 2007, 45: 3620-3625.
11. Guion CE, Ochoa TJ, Walker CM, et al.: Detection of diarrheagenic Escherichia coli by use of melting-curve analysis and real-time multiplex PCR. J Clin Microbiol 2008, 46: 1752-1757.
12. Cabada MM, Maldonado F, Quispe W, et al.: Risk factors associated with diarrhea among international visitors to Cuzco, Peru. Am J Trop Med Hyg 2006, 75: 968-972.
13. Steffen R, Tornieporth N, Clemens SA, et al.: Epidemiology of travelers' diarrhea: Details of a global survey. J Travel Med 2004, 11: 231-237.
14. Shlim R. Looking for evidence that personal hygiene precautions prevent traveler's diarrhea. Clin Infect Dis 2005, 41(suppl 8): S531-S535.
15. Zhu H, Hart CA, Sales D, Roberts NB: Bacterial killing in gastric juice - effect of pH and pepsin on Escherichia coli and Helicobacter pylori. J Med Microbiol 2006, 55: 1265-1270.
16. MartinsenATC, Bergh K, Waldum HL: Gastric juice: a barrier against infectious diseases. Basic Clin Pharmacol Toxicol 2005, 96: 94-102.
17. Tennant SM, Hartland EL, Phumoonna T, et al.: Influence of gastric acid on susceptibility to infection with ingested bacterial pathogens. Infect Immun 2008, 76: 639-645.
18. Neal RK, Scott HM, Slack RCB, Logan RFA: Omeprazole as a risk factor for Campylobacter gastroenteritis: Case-control study. BMJ 1996, 312: 414-415.
19. Neal RK, Brij OS, Slack BCR, et al.: Recent treatment with H2 antagonists and antibiotics and gastric surgery as risk factors for salmonella infection. BMJ 1994, 308: 176.
20. Bourret TJ, Porwollik S, McClelland M, et al.: Nitric oxide antagonizes the acid tolerance response that protects Salmonella against innate gastric defenses. PLoS ONE 2008, 3: E1833.
21. Benjamin N, O'Driscoll F, Dougall H, et al.: Stomach NO synthesis. Nature 1994, 368: 502.
22. Lin PW, Simon PO Jr, Gewirtz AT, et al.: Paneth cell cryptdins act in vitro as apical paracrine regulators of the innate inflammatory response. J Biol Chem 2004, 279: 19902-19907.
23. Aldred PMR, Hollox EJ, Armour JAL: Copy number polymorphism and expression level variation of the human-defensin genes DEFA1 and DEFA3. Hum Mol Genet 2005, 14: 2045-2052.
24. Hollox EJ, Armour JAL, Barber JCK: Extensive normal copy number variation of a b-defensin antimicrobial-gene cluster. Am J Hum Genet 2003, 73: 591-600.
25. Legrand D, Elass E, Pierce A, Mazurier J: Lactoferrin and host defence: an overview of its immuno-modulating and anti-inflammatory properties. Biometals 2004, 17: 225-229.
26. Togawa J, Nagase H, Tanaka K, et al.: Oral administration of lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance. J Gastroenterol Hepatol 2002, 17: 1291-1298.
27. Gomez HF, Ochoa TJ, Carlin LG, Cleary TG: Human lactoferrin impairs virulence of Shigella flexneri. J Infect Dis 2003, 187: 87-95.
28. Orsi N: The antimicrobial activity ofClactoferrin: current status and perspectives. Biometals 2004, 17: 189-196.
29. Ochoa TJ, Chea-Woo E, Campos M, et al.: Impact of lactoferrin supplementation on growth and prevalence of Giardia colonization in children. Clin Infect Dis 2008, 46: 1881-1883.
30. Greenberg DE, Jiang, ZD, Steffen R, et al.: Markers of inflammation in bacterial diarrhea among travelers, with a focus on enteroaggregative Escherichia coli pathogenicity. J Infect Dis 2002, 185: 944-949.
31. Bouckenooghe AR, Dupont HL, Jiang ZD, et al.: Markers of enteric inflammation in enteroaggregative Escherichia coli diarrhea in travelers. Am J Trop Med Hyg 2000, 62: 711-713.
32. Mohamed JA, DuPont HL, Jiang ZD, et al.: A novel single-nucleotide polymorphism in the lactoferrin gene is associated with susceptibility to diarrhea in North American travelers to Mexico. Clin Infect Dis 2007, 44: 945-952.
33. AllenRSJ, Crown SE, Handel TM: Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol 2007, 25: 787-820.
34. Charo IF, Ransohoff RM: The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006, 354: 610-621.
35. Sansonetti PJ, Arondel J, Huerre M, et al.: Interleukin-8 controls bacterial transepithelial translocation at the cost of epithelial destruction in experimental Shigellosis. Infect Immun 1999, 67: 1471-1480.
36. Jiang ZD, Okhuysen P, Guo DC, et al.: Genetic susceptibility to enteroaggregative Escherichia coli diarrhea: Polymorphism in the interleukin-8 promotor region. J Infect Dis 2003, 188: 506-511.
37. Jiang ZD, DuPont HL, Garey K, et al.: A common polymorphism in the interleukin 8 gene promoter is associated with Clostridium difficile diarrhea. Am J Gastroenterol 2006, 101: 1112-1116.
38. Jiang ZD, Garey KW, Price M, et al.: Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea. Clin Gastroenterol Hepatol 2007, 5: 964-968.
39. Marionneau S, Ruvoen N, Le Moullac-Vaidye B, et al.: Norwalk virus binds to histo-blood group antigens present on gastro-duodenal epithelial cells of secretor individuals. Gastroenterology 2002, 122: 1967-1977.
40. Lindesmith L, Moe C, Marionneau S, et al.: Human susceptibility and resistance to Norwalk virus infection. Nat Med 2003, 9: 548-553.
41. Kirkpatrick BD, Haque R, Duggal P, et al.: Association between Cryptosporidium infection and human leukocyte antigen class I and class II alleles. J Infect Dis 2008, 197: 474-478.
42. Duggal P, Haque R, Roy S, et al.: Influence of human leukocyte antigen class II alleles on susceptibility to Entamoeba histolytica infection in Bangladeshi children. J Infect Dis 2004, 189: 520-526.
43. Petri WA, Miller M, Binder HJ, et al.: Enteric infections, diarrhea, and their impact on function and development. J Clin Invest 2008, 118: 1277-1290.
44. Adachi JA, Ericsson CD, Jiang ZD, et al.: Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico. Clin Infect Dis 2003, 37: 1165-1171.
45. Ericsson CD, DuPont HL, Okhuysen PC, et al.: Loperamide plus azithromycin more effectively treats TD in Mexico than azithromycin alone. J Travel Med 2007, 14: 312-319.
46. DuPont HL, Jiang ZD, Okhuysen PC, et al.: A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med 2005, 142: 805-812.
47. Dupont HL, Jiang ZD, Belkind-Gerson J, et al.: Treatment of travelers' diarrhea: Randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone. Clin Gastroenterol Hepatol 2007, 5: 451-456.
48. Glenn GM, Villar CP, Flyer DC, et al.: Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: Use of skin pretreatment to disrupt the stratum corneum. Infect Immun 2007, 75: 2163-2170.
49. McKenzie R, Bourgeois AL, Frech SA, et al.: Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): Protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine 2007, 25: 3684-3691.